0
0
December 10, 2025
NEW YORK — For years, millions of women struggling with Polycystic Ovary Syndrome (PCOS) have been offered little more than birth control pills and advice to “just lose weight” to manage their symptoms. Now, a quiet revolution is underway in clinics across the United States.
According to a sweeping new analysis of 120 million patient records released Tuesday, prescriptions for powerful GLP-1 weight-loss drugs among women with PCOS have surged sevenfold since 2021. The data, provided by health analytics firm Truveta, reveals that patients and doctors are increasingly bypassing standard guidelines to access treatments that—unlike traditional therapies—address the metabolic roots of the disorder.
“We’re seeing that patients with PCOS are becoming a slightly larger proportion of the overall population of people who have a GLP-1 prescription,” said Karen Gilbert Farrar, a senior research analyst at Truveta.
The findings highlight a growing disparity between clinical practice and regulatory approval. While drugs like semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) are FDA-approved for diabetes and obesity, none are officially approved for PCOS. Yet, for many women, they are the first intervention that has ever worked.
The Data: A Massive Shift in Care
The Truveta report paints a stark picture of a shifting landscape in women’s health. In 2021, only 2.4% of women with a PCOS diagnosis were prescribed a GLP-1 medication. By 2025, that figure had skyrocketed to 17.6%.
PCOS affects an estimated 8% to 13% of reproductive-aged women globally. It is a leading cause of infertility and is characterized by hormonal imbalances, irregular periods, and cysts on the ovaries. Crucially, it is also deeply tied to metabolic health; up to 80% of women with PCOS have insulin resistance, which drives stubborn weight gain and exacerbates other symptoms.
“It’s this chicken versus egg phenomenon,” explained Dr. Judith Korner, an endocrinologist and obesity specialist. “There’s insulin resistance that causes or worsens PCOS.”
Beyond the Scale: Patient Stories
For Tai Adaya, a 35-year-old business owner from New York, the drugs have been life-altering. Like many, she spent years cycling through treatments like metformin and diet changes with little success.
“I wish that every young woman diagnosed with PCOS, instead of metformin or diet, had this presented as an option,” Adaya told Reuters. “I do think it can save a lot of years.”
After starting a low dose of tirzepatide (Zepbound), Adaya lost 15 to 20 pounds. More importantly, her menstrual cycle—often absent or erratic in PCOS patients—became regular within three months.
Because she does not have a diabetes diagnosis and the drugs are not on-label for PCOS, Adaya pays out of pocket, a common hurdle that limits access to those with financial means. “It does feel like another instance where women’s health is being deprioritized,” she added.
The Science: Why It Works
GLP-1 receptor agonists work by mimicking a hormone that targets areas of the brain that regulate appetite and food intake. However, their impact on insulin sensitivity is likely the key for PCOS patients.
When insulin levels are high, the ovaries are stimulated to produce excess testosterone, which halts ovulation and causes symptoms like acne and facial hair growth. By lowering insulin levels and reducing weight, GLP-1 drugs break this vicious cycle.
“PCOS causes weight gain and aspects of the disease get better with weight loss,” noted Dr. Angela Fitch, a Massachusetts-based obesity specialist and former president of the Obesity Medicine Association.
While weight loss is the primary driver of symptom relief, emerging research suggests these drugs may also have direct effects on ovarian function, though more data is needed.
The “Missed Opportunity”
Despite the clear demand and clinical success, pharmaceutical giants have been slow to formalize these benefits. Neither Novo Nordisk nor Eli Lilly is currently running late-stage clinical trials specifically targeting PCOS.
Dr. Fitch described this as a “missed opportunity for women’s health.” She highlighted a specific gap for “lean PCOS” patients—women who have the metabolic disorder but are not overweight. Because current approvals for these drugs are tied to BMI (Body Mass Index), women with lean PCOS often cannot access them, even if their insulin resistance is severe.
“It’s hard to get a large pharmaceutical company to want to have an indication for normal-weight PCOS when the vast majority of PCOS has weight issues,” Fitch said.
Implications for Public Health
The widespread off-label use of these drugs raises significant public health questions.
1. Access and Equity: With costs running upwards of $1,000 per month without insurance coverage, the treatment gap is likely to widen between wealthy patients and those relying on Medicaid or standard insurance plans that strictly enforce FDA indications.
2. The “Ozempic Baby” Boom: As these drugs restore ovulation in women who were previously infertile, unintended pregnancies are becoming more common. Doctors are now urging patients starting GLP-1s to use effective contraception if they are not planning to conceive.
3. Long-term Safety: While the drugs have a strong safety profile for diabetes and obesity, their long-term impact specifically on reproductive hormones in younger women remains understudied.
Looking Ahead
The medical community is calling for dedicated clinical trials to establish dosing protocols and safety guidelines specifically for PCOS. Until then, doctors are voting with their prescription pads, filling a void that research and regulation have left open.
For patients like Adaya, the waiting game is over. “It is frustrating to hear that this patient population is not a priority,” she said. But for now, even without the official stamp of approval, she finally has a treatment that works.
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
-
Primary Reporting: Satija, B., & Respaut, R. (2025, December 9). Weight-loss drugs fill a treatment gap for women with hormone disorder PCOS, doctors say. Reuters.
